COVID-19 vaccine cohort for special populations FRESH-PEF73983-en Aude BARQUIN COVID-19 vaccine cohort for special populations ANRS 0001 S COV-POPART FRESH-PEF73983-en 73983 FRESH-PEF73983 Linda WITTKOP Paul LOUBET Odile LAUNAY AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) Epidemiology France Portal (PEF) AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) null Sophie;GUILMIN-CREPON Aude;BARQUIN Covid-19 vaccines / Immunogenicity / Immunosuppression / At-risk populations Clinical immunology Infectious disease medicine COVID-19 Main objectives common to all sub-populations: To evaluate in a standardized way in each sub-population the humoral immune response to Covid-19 vaccination at 1, 6, 12, 24 months after the first injection (one-injection scheme) or after the second injection of the vaccine (two- or three-injection schemes) and to evaluate in a standardized way the humoral response 1 month after receipt of the third injection in participants receiving a third injection according to current recommendations... Secondary objectives common to all sub-populations: 1. to evaluate and characterize the antigen-specific T-lymphocyte cellular immune response (at INC, M06, M12 and M24) induced after the first injection (one-injection regimen) or after the second injection of the vaccine (two- or three-injection regimens) in each subpopulation.. 2. compare the humoral immune response at 1, 6, 12, 24 months after the first injection (single-injection regimen) or after the second injection of the vaccine (two- or three-injection regimens) in each subpopulation with a group of subjects free of the chronic conditions studied or other pathologies/treatments influencing the immune response 3. compare the humoral response after three injections (M02) with that after two injections (M01) in participants who received a third injection in accordance with current recommendations.. 4. to evaluate and characterize the humoral immune response of participants who received a booster dose of mRNA vaccine in accordance with current recommendations 5. in each subpopulation, study the factors associated with the humoral immune response at 1 month and with the persistence of the humoral immune response at 6, 12 and 24 months as a function of age, stage of disease, treatment, type of vaccine (as well as the specific characteristics of the subpopulations studied) 6. compare the humoral immune response between different subpopulations 7. describe seroconversion for anti-nucleoprotein antibodies at inclusion and during follow-up 8. immuno-virological characterization of vaccine failures (SARS-CoV-2 infection within the time frame defined by current protocol) 9. investigate the genetic determinants of the immune response according to the underlying pathology and current treatments, if any (response and resistance to vaccination) Secondary objectives of the subpopulation of subjects not suffering from one of the chronic conditions of interest or other pathologies / under treatment with a known influence on the immune response and vaccinated with a 1st injection of Astra-Zeneca AZD1222 vaccine who will be vaccinated with a 2nd injection of Pfizer BNT162b2 mRNA vaccine 1. compare the immune response (humoral and cellular) obtained before and after the BNT162b2 vaccine dose 2. assess clinical reactogenicity (local and general) after an injection of BNT162b2 vaccine administered in accordance with current recommendations after an injection of AZD1222 vaccine null France Individuals General population Male Female Child, Preschool (2 to 5 years) Child (6 to 12 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Clinical data Participant-reported health data Biological data Socio-demographic data Concomitant Pathologies: ICD-10. Ongoing Treatments: WHO Drug CMG-EC quality system (ISO 9001 certified) consistency checks after data entry data monitoring according to a monitoring plan: remotely + on site by a specialised CRO (return to source file for data management and verification) Other Through organizations (health services or institutions schools businesses etc.) Converting or copying information into a structured record Medico-administrative database Observational Study Observational Study Cohort study Enrolments closed on 31 December 2021 in the adult cohort: 6,112 participants. Enrolments ongoing in the paediatric ancillary study: enrolment target of 810 participants (enrolment expected to close in July 2022). Unknown Restricted access Via the PRS form, which must be validated by the cohort's Steering Committee and Scientific Board.